clinical trials and promising treatment

 Friday September 20

In the fight against Alzheimer's disease, France is in a very good position. Alzprotect has been authorized to conduct clinical trials for a promising drug.

 

Alzheimer: Alzprotect launches clinical trial

The fight against Alzheimer's disease continues and research is advancing rapidly. In France, the Alzprotect company based in Lille, has received authorization from the French National Medicines Agency to launch a clinical trial in patients with progressive supranuclear palsy (PSP), a rare neurodegenerative disease that can be transferred to Alzheimer's.

Objectives of this clinical trial, to check whether PSP patients tolerate the drug well, " strengthen the pharmacokinetic data of the product in patients after 3 months of treatment but also to assess the impact of treatment on markers of the disease (more than 20 markers) »Announces Alzprotect on its website.

 

Promising treatment

This study will be conducted by Professor Corvol at La Pitié Salpêtrière hospital in Paris and should be completed by the end of 2023. For 3 months, the 36 participants will alternately receive a placebo or one of the two doses of AZP2006 (60 and 80-then-50 milligrams) then an observation period of 3 months corresponding to weaning will be carried out. It will then be necessary to wait until 2021 to know the results.

The fruit of long years of research, this treatment is showing promise, believes Philippe Verwaerde, CEO of Alzprotect. On the eve of World Alzheimer's Day, which will take place on Saturday September 21, 2019, hope is therefore allowed for patients with progressive supranuclear palsy.

To date, there is no treatment for this disease. France is nevertheless at the forefront of world research against Alzheimer's disease thanks in particular to the work of the Institut Pasteur com Lille. the researchers of this reference laboratory have indeed identified three quarters of the genes responsible for Alzheimer's and are preparing to launch a large international study.

 Perrine Deurot-Bien